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Summary 
A 33 year old gentleman of Egyptian heritage presented with a 21 year history of unexplained and 
recurrent hypercalcaemia, nephrolithiasis, nephrocalcinosis and myocarditis. A similar history was also 
found in two first-degree relatives. Further investigation into the Vitamin D metabolism pathway identified 
the biochemical hallmarks of Infantile Hypercalcaemia Type 1 (IIH) [1]. A homozygous, likely pathogenic, 
variant in CYP24A1 was found on molecular genetic analysis confirming the diagnosis. Management now 
focuses on removing excess Vitamin D from the metabolic pathway as well as reducing calcium intake to 
achieve serum adjusted calcium to the middle of the reference range. If undiagnosed, IIH can cause serious 
renal complications and metabolic bone disease. 
Learning points 
• Infantile hypercalcaemia Type 1 (IIH) is an autosomal recessive disorder characterised by 
homozygous mutations in the CYP24A1 gene that encodes the 24-hydroxylase enzyme used to 
convert active Vitamin D metabolites such as 1,25-(OH)2-Vitamin D, into their inactive form. 
• IIH should be questioned in individuals presenting with a history of unexplained hypercalcaemia, 
especially if presenting from childhood and/or where there is an accompanying family history of 
the same in 1st and/or 2nd degree relatives, causing complications such as nephrocalcinosis, 
pericarditis and calcium based nephrolithiasis.  
• Associated biochemistry of IIH is persistent mild to moderate hypercalcaemia, normal or raised 25-
(OH)-Vitamin D and elevated 1,25-(OH)2-Vitamin D. An elevated ratio of 25-(OH)-Vitamin D to 
24,25-(OH)2-Vitamin D can be a useful marker of defects in the 24-hydroxylase enzyme, whose 
measurement can be facilitated through the supra-regional assay service 
• Management should focus on limiting the amount of Vitamin D introduced into the body either via 
sunlight exposure or supplementation in addition to calcium dietary restriction to try and maintain 
appropriate calcium homeostasis 
Background  
Vitamin D excess, either as a result of excess intake or reduced inactivation/excretion, is recognised to be a 
cause of hypercalcaemia, although seldom considered. Subtle elevations in the 25-(OH) and 1,25-(OH)2 
forms of Vitamin D can go unnoticed and be poorly understood. The condition we describe here is under-
recognised in clinical practice. When these individuals are eventually diagnosed as adults, they commonly 
are found to have had biochemical/pathological features extending back from childhood [2]. We present 
this case to provide further education and prevent other patients from undergoing the same significant 
delay in appropriate diagnosis. 
Case presentation 
A 33 year old gentleman of Egyptian heritage incidentally came to the attention of endocrinology during an 
admission to acute medicine presenting with symptoms of chest pain thought to be the 8th presentation in 
4 years with myocarditis associated symptoms. Cause for the myocarditis was documented in cardiology 
outpatient letters as being “undetermined.” The patient did not have any other classical features on history 
or examination associated with hypercalcaemia on this presentation.  
The patient had an extensive past medical history of renal calculi- first presenting at age 12 whilst still living 
in Egypt. Subsequent repeat renal calculi developed at age 16 and 17. The patient had an otherwise normal 
development history through his childhood. He then presented to urology services in the UK as an adult 
due to hydronephrosis secondary to renal calculi. Both brother and father of this patient also suffered from 
nephrolithiasis indicating a possible genetic aetiology to the shared symptoms. The patient had also been 
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reviewed in a metabolic renal stone clinic. 
The patient did not have specific findings on clinical examination aside from the symptoms associated with 
the myocarditis of chest pain and shortness of breath, and renal angle abdominal pain whenever renal 
calculi arose.   
Investigation 
A summary of biochemical and radiological investigations is documented in Table 1. Other investigations 
performed include renal calculus analysis by infrared spectroscopy in 2009 which revealed 98% content of 
the extracted calculus was calcium phosphate. Repeated oxalate and citrate output demonstrated results 
either within the reference range or only mildly elevated (Citrate output- 1.4mmol/24hrs [reference range - 
1.3-6.0mmol/24hrs], Oxalate output- 380umol/24hrs [reference range <460umol/24hrs]). Fibroblast 
Growth Factor-23 (FGF-23) and Retinol binding protein (RBP) levels were checked historically as part of his 
initial work up in 2011 and were within the reference range when measured (RBP/creatinine ratio – 
5.0ug/mmol creatinine [reference range <18ug/mmol creatinine], FGF23 – 93RU/ml [reference range 
<100RU/ml]).  FGF-23 is one of the most important regulators of serum phosphate and 1,25-(OH)2-Vitamin 
D levels. High levels of FGF 23 suppresses the activity of 1-Alfa Hydroxylase activity leading to low 1,25-
(OH)2-Vitamin D levels [3]. However FGF-23 deficiency or resistance can lead to a state of high 1,25-(OH)2-
Vitamin D levels with high phosphate levels. There are hereditary and acquired forms of FGF-23 
deficiency/resistance and this manifest with tumoral calcinosis [3]. RBP is used by renal physicians to rule 
out renal tubular injury as a cause of underlying renal disease. This patient had been followed up by the 
renal team for number of years for unexplained nephrocalcinosis and he would have had a RBP level 
checked initially to rule out Renal tubular damage. 
As part of this patients Hypercalcemia work up he also had a DEXA scan showed consistent signs of 
osteopenia (T-score between -1 to -2.5) within the lumbar spine region.  
In June 2020, a 24,25-(OH)2-Vitamin D level performed at Norwich and Norfolk Hospital Supra-regional 
assay lab returned a result of 1.2nmol/L (reference range- 1.1-13.5nmol/L). With an accompanying 25-OH-
Vitamin D of 79nmol/L, this yielded a significantly elevated 25-OH-Vitamin D to 24,25-(OH)2-Vitamin D ratio 
of 66 (upper limit of normal = 23). A mildly elevated 1,25-(OH)2-Vitamin D (153pmol/L [reference range 55-
139nmol/L]) means the ratio of 1,25-(OH)2-Vitamin D to 24,25-(OH)2-Vitamin D was extremely high at 128, 
a further feature of IIH. Genetic analysis by next-generation sequencing of CYP24A1 revealed a biallelic 3 
base pair deletion at codon 143 (Glu143del) that has a deleterious effect on the enzyme and classified as a 
class 4 variant (likely pathogenic) [4]. Given both biochemical and genetic hallmarks were concordant – a 
diagnosis of IIH was made. 
Treatment  
Prior to the diagnosis, the patient was prescribed: Indapamide 2.5mg once daily, Nebivolol 2.5mg twice 
daily. The treatment plan for this patient following diagnosis aimed to reduce his intake of dietary calcium 
as well as any medications which could exacerbate hypercalcaemia. Additionally, exogenous sources of 
Vitamin D which could exacerbate his 1,25-(OH)2-Vitamin D were removed. The summary of the initial 
treatment plan was as follows: 
• Avoid all exogenous Vitamin D supplementation 
• Avoid prolonged sun exposure which may increase production of active vitamin D 
• Reduce dietary calcium intake titrating this against achieving a serum calcium within the middle of 
the reference range (2.2-2.6mmol/L) 
If this failed to correct his serum calcium then next treatment trial would be oral fluconazole. Acute 
presentations with markedly elevated serum calcium levels could be treated with short courses of 
prednisolone to inhibit 1,25-(OH)2-Vitamin D levels.  
Outcome and follow-up   
As a first step, Renal Dietetic input will start working to achieve a low calcium diet and instructions to care 
providers for the patient to not introduce any exogenous sources of Vitamin D. At time of manuscript 
submission, this has been slow to initiate, but regular follow-up is planned on diet adherence with repeated 
biochemistry, to identify if next line therapy (trial of fluconazole) is indicated. Other first degree relatives of 
the patient have been advised to be screened for the same mutation to confirm carrier/affected status of 
the parents and siblings respectively. 
Discussion  
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IIH is a rare condition with its prevalence in the general population unknown [1].  In the UK, there had been 
concerns of Vitamin D induced Hypercalcaemia in some children as far back as the 1950’s. Interestingly this 
was the same time at which Vitamin D supplication or food fortification was introduced to prevent Rickets 
disease. There were 204 reported cases within a two year period up to July 1955 [2]. In the vast majority it 
was thought to be due to high intake of Vitamin D. This would suggest disorders of Vitamin D metabolism 
are more prevalent but only some present with symptoms due to phenotypic variability [5].  
Infantile Hypercalcaemia is not a “benign” condition as initially postulated and in our patient he 
experienced Nephrocalcinosis, Osteopenia, GI symptoms and pericarditis [4].  
There are two known causative genes/”types” of Infantile Hypercalcaemia.  Type 1 is caused by loss of 
function mutation in CYP24A1 whilst Type 2 is caused by mutation in SLC34A1 gene. Mutation in CYP24A1 
leads to the phenotype we describe here (figure 1). Mutation in SLC34A1 reduces serum phosphate levels 
due to a defect in sodium dependant phosphate transporters, leading to low body stores of phosphates, 
and for which more Vitamin D is activated to compensate. 
Pragmatically for clinical practice, a pattern of high calcium, low PTH in a young person with no concerns of 
malignancy should prompt to check 1,25-(OH)2-Vitamin D level in addition to 25-OH-Vitamin D.  An 
inappropriately high 1,25-(OH)2-Vitamin D levels should prompt reflection on possible causes related to 
Vitamin D metabolism and further testing of other Vitamin D metabolites. Persistently high level of 1,25-
(OH)2-Vitamin D leads to increased intestinal absorption of Calcium as well as increased bone resorption.  
This sustained bone resorption leads to the osteopenia/osteoporosis described in this case [6]. 
Measurement of 24,25-(OH)2-Vitamin D is available to request through the supra-regional Vitamin D assay 
service at Norwich and Norfolk Hospitals in partnership with University of East Anglia [7]. This uses a liquid-
chromatography, tandem mass spectroscopy (LC-MS/MS) method and provides a level of 24,25-(OH)2-
Vitamin D as well as a ratio of 25-(OH)-Vitamin D to 24,25-(OH)2-Vitamin D. Sample requirements for 24,25-
(OH)2-Vitamin D are 100uL of separated serum sent at room temperature. The ratio of 25-(OH)-Vitamin D 
to 24,25-(OH)2-Vitamin D has a cut-off of >23 for being associated with altered Vitamin D status [8] 
Ultimately, the diagnosis is confirmed by identifying biallelic pathogenic variants. The Online Mendelian 
Inheritance in Man (OMIM) catalogue describes a range of mutations found in literature to cause IIH, 
including the Glu143del variant found in our patient [4 -> 5]. CYP24A1 testing is part of the NHS England 
National Genomic Testing Directory within panel R256 for nephrolithiasis [9] 
Treatment of this condition is potentially simple to initiate but can be challenging to maintain. Primarily 
treatment should be aimed at reducing Vitamin D and calcium intake in addition to avoiding prolonged sun 
exposure. Short courses of steroids can be used, however in the long term this is not feasible and there are 
case reports of successful use of Fluconazole given this inhibits the 1-α-Hydroxylase enzyme [10]. 
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Legends to tables/figures/videos  
Table 1 - Summary of historical patient investigations - results described with accompanying reference 
ranges 
Figure 1 – A summary of the Vitamin D metabolic pathway including enzymes and location of activity. The 
enzyme affected by IIH is highlighted by a red box. Red arrows indicate the expected changes in 
measureable vitamin D metabolites in IIH. Adapted from Figure 1A, Tebben et al [1]. 
 
  
